1
|
Wiggins BS, Dixon D, Bellone J, Gasbarro N, Marrs JC, Tran R. Key Articles and Guidelines in the Management of Dyslipidemia: 2019 Update. J Pharm Pract 2019; 33:882-894. [DOI: 10.1177/0897190019868413] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Although the mortality from cardiovascular disease has declined, it remains the leading cause of morbidity and mortality in the United States. Dyslipidemia is a modifiable risk factor that plays a significant role in the development of atherosclerotic cardiovascular disease. Treating dyslipidemia by lowering cholesterol, predominately low-density lipoprotein cholesterol, has been shown to reduce cardiovascular events. The first article that provided dyslipidemia bibliographies was published in 2006. Since this time, new therapies have become available and older therapies that were once thought to provide benefit have since been shown to lack positive outcomes and have therefore fallen out of favor for routine use. As the body of evidence continues to expand, clinicians are faced with reevaluating their treatment strategies to ensure optimal outcomes and appropriate use of lipid-lowering therapies. Therefore, this compilation was created to serve as a resource for clinicians. This publication provides an update of key articles in dyslipidemia management including various guidelines and practice-changing randomized controlled trials.
Collapse
Affiliation(s)
| | - Dave Dixon
- Virginia Commonwealth University School of Pharmacy, Richmond, VA, USA
| | | | | | - Joel C. Marrs
- University of Colorado Anschutz Medical Campus, Aurora, CO, USA
| | - Rebecca Tran
- Keck Graduate Institute School of Pharmacy, Claremont, CA, USA
| |
Collapse
|
2
|
Abstract
Hypertension affects 80 million people in the United States. It remains poorly controlled, with only 54% of diagnosed patients treated to blood pressure targets. Hypertension management is complex in part due to the volume of antihypertensive agents, variable patient needs and responses, and inconsistent design and outcomes from clinical trials. Therefore, trustworthy clinical practice guidelines have a key role in hypertension management. The United States experienced a 10-year gap in publication of hypertension guidelines, followed by multiple guideline publications in 2013. These guidelines led to more controversy than clarity, as there was discordance among them. This review summarizes the guidelines and clinical statements influencing the current debate in order to facilitate appropriate application.
Collapse
Affiliation(s)
- Toni L. Ripley
- Department of Pharmacy, Clinical and Administrative Sciences, University of Oklahoma College of Pharmacy, Oklahoma City, OK, USA
| | - Mary Baumert
- Siouxland Community Health Center, University of Nebraska Medical Center, Omaha, NE, USA
| |
Collapse
|